Table 1.
Baseline characteristics of the patients included in the study
| All | No diabetes | Glucocorticoid induced diabetes | |
|---|---|---|---|
| Incidence (95% CI) | N = 171 100% |
n = 133 78% (72%–85%) |
n = 38, 4 patients treated with insulin 22% (16%–28%) |
| Age, years, mean (min-max) | 64 (23–101) | 63 (23–101) | 66 (30–92) |
| Sex (% female) | 50 | 51 | 45 |
| Type of cancer | |||
| • Primary brain tumor | 117 (68%) | 93 (70%) | 24 (63%) |
| • Secondary brain tumor (metastasis) | 39 (23%) | 30 (23%) | 9 (24%) |
| • Unclassified | 15 (9%) | 10 (7%) | 5 (13%) |
| Performance status | |||
| • 0 | 62 (36%) | 49 (37%) | 13 (34%) |
| • 1 | 62 (36%) | 50 (38%) | 12 (32%) |
| • 2 | 27 (16%) | 20 (15%) | 7 (18%) |
| • 3 | 11 (7%) | 7 (5%) | 4 (10%) |
| • 4 | 4 (2%) | 3 (2%) | 1 (3%) |
| • Unclassified | 5 (3%) | 4 (3%) | 1 (3%) |
| Smoking | |||
| • Never smoker | 80 (47%) | 58 (44%) | 22 (58%) |
| • Smoking now or previously | 87 (51%) | 71 (53%) | 16 (42%) |
| • Missing | 4 (2%) | 4 (3%) | 0 (0%) |
| Antihypertensive therapy | 47 (28%) | 33 (25%) | 14 (37%) |
| Lipid-lowering therapy | 31 (18%) | 19 (14%) | 12 (32%) |
| Symptomatic atherosclerosis | 14 (8%) | 10 (8%) | 4 (11%) |
| Liver disease | 1 (1%) | 1 (1%) | 0 |
| Pancreatic disease | 0 (0%) | 0 | 0 |
| Number of glucose measurements in the 7 days observation period, median (IQR) | 10 (7–14) | 9 (6–12) | 15 (11–18) |
| Cumulative prednisolone dose, mg, mean in the 7 days observation period (min-max) | 674 (150–2150) | 668 (150–2150) | 693 (475–1050) |